aTyr Pharma reports clinical benefit for efzofitimod across multiple diseases

aTyr Pharma (ATYR) presented additional findings from the Phase 3 EFZO-FIT study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease, in a late-breaking oral abstract presentation at the European Respiratory Society Congress 2025 in Amsterdam. Improvements observed for the KSQ-Lung, FAS and KSQ-General Health scores were achieved rapidly and sustained robustly throughout the study. Despite missing the primary endpoint of the study, efzofitimod has demonstrated the potential to improve multiple disease-related health outcomes, including cough, shortness of breath, fatigue and general health. Treatment with efzofitimod was also associated with a trend toward a greater proportion of patients achieving steroid-free status for at least six months. The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48. However, clinical benefit for 5.0 mg/kg efzofitimod was observed across multiple study efficacy parameters at week 48 compared to placebo, including complete steroid withdrawal and KSQ-Lung score improvement, improvement in KSQ-Lung score change from baseline, preservation of forced vital capacity and a well-tolerated safety profile.